Search results
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Forbes· 1 day agoPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. PFE stock was trading at $52 in early June 2022, just before ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via Yahoo News· 6 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Is It Too Late to Buy Pfizer Stock?
The Motley Fool via AOL· 4 days agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 6 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Kansas Attorney General Kris Kobach sues Pfizer for COVID-19 vaccine
WIBW Topeka· 16 hours agoKansas Attorney General Kris Kobach on Monday morning announced he is suing Pfizer for what he said...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 5 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Kansas Attorney General Kris Kobach sues Pfizer over marketing of COVID-19 vaccine
The Kansas City Star· 15 hours agoKansas Attorney General Kris Kobach is suing the pharmaceutical company Pfizer, alleging it deceptively marketed its COVID-19 vaccine. The lawsuit, filed in state court in ...
Childress Capital Advisors LLC Has $583,000 Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 4 days agoChildress Capital Advisors LLC boosted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities ...
Is It Too Late to Buy Pfizer Stock? | The Motley Fool
The Motley Fool· 4 days agoAre Pfizer's (PFE -0.43%) best days behind it? If the stock's critics are to be believed, the answer...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoPfizer disclosed on May 7 that a child participating in another...